1-4 of 4
Valerie Ironside
Close
Sort by
Journal Articles

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Clinical Trials & Observations
Judith E. Karp, Tatiana I. Vener, Mitch Raponi, Ellen K. Ritchie, B. Douglas Smith, Steven D. Gore, Lawrence E. Morris, Eric J. Feldman, Jacqueline M. Greer, Sami Malek, Hetty E. Carraway, Valerie Ironside, Steven Galkin, Mark J. Levis, Michael A. McDevitt, Gail R. Roboz, Christopher D. Gocke, Carlo Derecho, John Palma, Yixin Wang, Scott H. Kaufmann, John J. Wright, Elizabeth Garret-Mayer
Journal: Blood
Blood (2012) 119 (1): 55–63.
https://doi.org/10.1182/blood-2011-08-370825
Published: 2012
Includes: Supplemental data
Journal Articles

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

Clinical Trials & Observations
Judith E. Karp, Karen Flatten, Eric J. Feldman, Jacqueline M. Greer, David A. Loegering, Rebecca M. Ricklis, Lawrence E. Morris, Ellen Ritchie, B. Douglas Smith, Valerie Ironside, Timothy Talbott, Gail Roboz, Son B. Le, Xue Wei Meng, Paula A. Schneider, Nga T. Dai, Alex A. Adjei, Steven D. Gore, Mark J. Levis, John J. Wright, Elizabeth Garrett-Mayer, Scott H. Kaufmann
Journal: Blood
Blood (2009) 113 (20): 4841–4852.
https://doi.org/10.1182/blood-2008-08-172726
Published: 2009
Includes: Supplemental data
Journal Articles

In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Rebecca M. Ricklis, MS, Judith E. Karp, MD, Eric J. Feldman, MD, Suzanne Galkin, BA, Jacqueline M. Greer, RN, Valerie Ironside, CRNP, Kim Mirjafary, Timothy D. Talbot, BA, Lawrence E. Morris, MD, John J. Wright, MD, PhD, Scott H. Kaufmann, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 914.
https://doi.org/10.1182/blood.V110.11.914.914
Published: 2007
Journal Articles

Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Judith E. Karp, MD, Eric J. Feldman, MD, Lawrence Morris, MD, Jacqueline Greer, RN, Valerie Ironside, RN, B. Douglas Smith, MD, Ellen Ritchie, MD, Steven D. Gore, MD, Mark J. Levis, MD,PhD, Scott H. Kaufmann, MD,PhD, Sami Malek, MD, John J. Wright, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 426.
https://doi.org/10.1182/blood.V108.11.426.426
Published: 2006